Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for

Treatment of Coronary Artery Disease

ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its outstanding clinical results," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Physicians in the United States have been waiting for years to treat their patients with a technology that delivers on the promise of drug eluting stents through both ease of use and excellent clinical performance, and XIENCE V is that technology."

The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build- up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.

"XIENCE V was designed to improve safety and efficacy compared to earlier generation stents. The long-term clinical data from two studies performed in both the United States and Europe have now confirmed that XIENCE V is a true next-generation drug elu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, ... delivery technologies, today announced that it has been selected ... & Industry Association,s 2014 Awards for Excellence ... by an independent panel of judges from SCORE (Counselors ... Award winners will be honored at a gala event ...
(Date:8/27/2014)... 27, 2014 After the boom of ... the next beverage craze is going to be the ... formulators can use Stress Relief energy pattern which can ... making of a beverage, including minerals, herbs and liquids. ... channeling that power into rapid recovery and helping to ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 WriteResult, ... services – has once again shown superiority when it ... sponsor by completing the ePRO portion of their most ... The Japan-based pharma chose WriteResult’s digital writing platform ... trials – the first to complete drew data from ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... established to develop bioelectronic technologies, today announced that it ... the U.S. Securities and Exchange Commission relating to a ... number of shares to be offered and the price ... determined. Jefferies LLC will act as the ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Genedata ... Diseases , ... June 1, 2010 -- Genedata, a leading provider of advanced software solutions for drug ... an ERA-Net-funded applied pathogenomics project, which is using systems biology to identify ...
... and BERLIN , May 31, 2010 ... in patients with IRon deficiency,and Chronic Heart Failure) study ... improve renal function in,chronic heart failure patients. Ferinject(R) is ... and iron deficiency anaemia. These,results were now presented at ...
... ... June 2nd and 3rd Live at www.BionConferenceLive.com , ... Boston, MA (Vocus) May 28, 2010 -- PlatformQ ... energy industries, and LabRoots , a free social networking site serving the scientific community, ...
Cached Biology Technology:Genedata Phylosopher Selected for ERA-NET sncRNA Project 2Genedata Phylosopher Selected for ERA-NET sncRNA Project 3Genedata Phylosopher Selected for ERA-NET sncRNA Project 4FAIR-HF Subanalysis Shows That Ferinject(R) Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure 2FAIR-HF Subanalysis Shows That Ferinject(R) Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure 3FAIR-HF Subanalysis Shows That Ferinject(R) Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure 4FAIR-HF Subanalysis Shows That Ferinject(R) Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure 5FAIR-HF Subanalysis Shows That Ferinject(R) Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure 6Dr. David Wolf, NASA Astronaut and Inventor, to Speak at BioConference Live 2Dr. David Wolf, NASA Astronaut and Inventor, to Speak at BioConference Live 3
(Date:8/27/2014)... pay a premium for fruits, vegetables and other foods ... claims is another matter. Now scientists studying conventional and ... sure farms are labelling their produce appropriately. Their report, ... Food Chemistry , could help prevent organic food fraud. ... Authority and the Wuerzburg University note that the demand ...
(Date:8/27/2014)... Outstanding basic research, a growing focus on ... patient care have earned the Herbert Irving Comprehensive ... (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year ... Institute (NCI). The grant renews the center,s status ... Centers in New York City and one of ...
(Date:8/27/2014)... health advocates, campaigns against trans-fats have largely succeeded ... taking aim at sugar for its potential contributions ... are still wrangling over the best way to ... an article in Chemical & Engineering News ... American Chemical Society. , In the article, Stephen ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... An antibacterial peptide developed by Laszlo Otvos, a ... Science and Technology, looks to be a highly-effective ... suffered by soldiers. Otvos and his collaborators ... was more effective than current antimicrobial chemotherapy measures ...
... consent before deciding whether to let researchers share their genetic ... team of investigators at Group Health Research Institute and the ... Asked," is in the September 2010 Journal of Empirical ... team,s knowledge, it is the first to ask research participants, ...
... technique using near infrared light enables scientists to look ... a new frontier in the fights against cancer and ... led by Professor Kevin Belfield, used near infrared light ... tumors deep within tissue. The probes specifically target lysosomes, ...
Cached Biology News:People want to be asked before sharing genetic data 2
... fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL each) , ... , Individual compounds are dissolved in DMSO ... mM. Supplied in 5 96-well trays. Dilute library ...
... interferons are cytopathic effect inhibition assays, also ... The neutralization assay measures the antibody's ability ... cytokine. Sample types include; tissue culture supernatents; ... assays, one unit is defined as the ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... SYS203 is a complete, flexible system ... small samples, as is frequently required ... designed around Instechs miniature Clark-style polarographic ... inch in diameter (3.2 mm), it ...
Biology Products: